Predict your next investment

Venture Capital
altapartners.com

See what CB Insights has to offer

Investments

431

Portfolio Exits

130

Funds

12

Service Providers

1

About Alta Partners

Alta Partners is a San Francisco-based venture capital firm focused on the life sciences area funding over 100 companies in the industry since 1996. They prefer to act as lead investor in the projects that they pursue and, when appropriate, take a board seat as part of the investment.

Alta Partners Headquarter Location

One Embarcadero Center Suite 3700

San Francisco, California, 94111,

United States

415-362-4022

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Alta Partners

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Alta Partners in 2 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

113 items

C

CB Insights Healthcare Smart Money Investors - 2020

25 items

Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.

Latest Alta Partners News

Kelonia Therapeutics Raises $50M in Series A Financing

Apr 29, 2022

Kelonia Therapeutics , a Boston, MA-based biotech company focused on in vivo gene delivery, raised $50m in Series A financing. Backers included Alta Partners, Horizons Ventures, Venrock and other investors. The company will use the funding to advance genetic medicines starting with an “off-the-shelf” chimeric antigen receptor (CAR) to treat hematologic cancer that may enable the clinical benefit of CAR T without the typical toxicities, advance other programs for oncology and non-oncology indications, and further expand its gene delivery platform and capabilities. Led by Kevin Friedman, Ph.D., President and Chief Scientific Officer, Kelonia is advancing genetic medicines using its gene delivery platform. The company’s in vivo gene delivery technology uses a few potent lentiviral vector-like particles to deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. By enabling precisely targeted, highly efficient, manufacturable “off-the-shelf” in vivo gene delivery, Kelonia’s technology has the potential to expand the impact and reach of genetic medicines to every patient in need. Based on discoveries made in the lab of Massachusetts Institute of Technology’s Michael Birnbaum, Ph.D., and leveraging research from scientists at the French National Centre for Scientific Research (CNRS), Kelonia’s in vivo gene delivery technology enables a few potent lentiviral vector-like particles armed with an adjustable targeting system to precisely, efficiently, and safely deliver payloads exactly where needed to treat a broad range of diseases. The company’s early applications combine oncology-targeted therapeutics, such as CAR and T cell receptor molecules, with Kelonia’s precision in vivo targeting technology. When used in concert, this combination enables potent and precise tumor targeting with limited “off-tumor” toxicity, which would otherwise be a concern. Administered directly in vivo as an “off-the-shelf” medicine, Kelonia’s transformational therapies in development for solid and hematologic tumors have the potential to democratize patient access to genetic medicines. Beyond oncology, the company will advance its technology to unlock delivery to previously hard-to-reach tissues, such as neurological, muscular or renal, to deliver different types of genetic cargo with the goal of radically transforming the treatment of diseases in these areas. In addition to the completion of its Series A, Kelonia has established strategic collaborations with Adimab and ElevateBio. Kelonia brings together industry leaders in cell and gene therapy responsible for the discovery and development of multiple clinical and commercial products including ABECMA®, the first FDA-approved anti-BCMA CAR T cell therapy product for relapsed or refractory multiple myeloma. The company’s leadership team includes Kevin Friedman, Ph.D., President and Chief Scientific Officer, Thomas Galbo, Ph.D., Chief Business Officer, and Molly Perkins, Ph.D., Vice President of Research. Kelonia’s scientific founders include Michael Birnbaum, Ph.D., Associate Professor of Biological Engineering, Massachusetts Institute of Technology, and Michael Fischbach, Ph.D., Associate Professor of Bioengineering and of Medicine, Stanford University, both world-leading experts in the fields of microbiology, immunology, oncology, and cell and gene engineering. The company’s board of directors comprises Michael Birnbaum, Michael Fischbach, Kevin Friedman, Bryan Roberts and Bob More, Managing Director at Alta. FinSMEs

Alta Partners Investments

431 Investments

Alta Partners has made 431 investments. Their latest investment was in Kelonia Therapeutics as part of their Series A on April 4, 2022.

CBI Logo

Alta Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/28/2022

Series A

Kelonia Therapeutics

$50M

Yes

7

4/19/2022

Series A

Free Market Health

$13.5M

Yes

3

4/14/2022

Series B

Be Biopharma

$130M

No

2

1/11/2022

Series C

Subscribe to see more

$99M

Subscribe to see more

10

11/4/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/28/2022

4/19/2022

4/14/2022

1/11/2022

11/4/2021

Round

Series A

Series A

Series B

Series C

Series B

Company

Kelonia Therapeutics

Free Market Health

Be Biopharma

Subscribe to see more

Subscribe to see more

Amount

$50M

$13.5M

$130M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

3

2

10

10

Alta Partners Portfolio Exits

130 Portfolio Exits

Alta Partners has 130 portfolio exits. Their latest portfolio exit was Tyra Biosciences on September 15, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/15/2021

IPO

$99M

8

6/29/2021

Acq - Pending

2

2/11/2021

IPO

$99M

7

10/11/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

5/9/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/15/2021

6/29/2021

2/11/2021

10/11/2019

5/9/2019

Exit

IPO

Acq - Pending

IPO

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

8

2

7

10

10

Alta Partners Acquisitions

1 Acquisition

Alta Partners acquired 1 company. Their latest acquisition was Bioventus on May 09, 2012.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/9/2012

$99M

Acq - Fin

Date

5/9/2012

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acq - Fin

Sources

Alta Partners Fund History

12 Fund Histories

Alta Partners has 12 funds, including Alta Partners NextGen Fund III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/19/2021

Alta Partners NextGen Fund III

$275M

2

6/12/2018

Alta Partners NextGen Fund I

Early-Stage Venture Capital

Closed

$130M

1

10/9/2006

Alta Partners VIII LP

Multi-Stage Venture Capital

Closed

$500M

1

12/31/2004

ACP IV LP

Subscribe to see more

Subscribe to see more

$99M

10

3/30/2004

Alta BioPharma Partners III LP Fund

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

2/19/2021

6/12/2018

10/9/2006

12/31/2004

3/30/2004

Fund

Alta Partners NextGen Fund III

Alta Partners NextGen Fund I

Alta Partners VIII LP

ACP IV LP

Alta BioPharma Partners III LP Fund

Fund Type

Early-Stage Venture Capital

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Closed

Subscribe to see more

Subscribe to see more

Amount

$275M

$130M

$500M

$99M

$99M

Sources

2

1

1

10

10

Alta Partners Service Providers

1 Service Provider

Alta Partners has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

Alta Partners Team

13 Team Members

Alta Partners has 13 team members, including current Founder, Managing Director, Guy P. Nohra.

Name

Work History

Title

Status

Guy P. Nohra

Founder, Managing Director

Current

Larry Randall

Chief Financial Officer

Current

Farah Champsi

InterWest Partners, and Robertson Stephens

Managing Director, General Partner

Current

Peter Hudson M.D.

iTriage, and EMA Partners

Managing Director

Current

Hilary Strain

Chief Financial Officer

Former

Name

Guy P. Nohra

Larry Randall

Farah Champsi

Peter Hudson M.D.

Hilary Strain

Work History

InterWest Partners, and Robertson Stephens

iTriage, and EMA Partners

Title

Founder, Managing Director

Chief Financial Officer

Managing Director, General Partner

Managing Director

Chief Financial Officer

Status

Current

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.